Compare BridgeBio Pharma Inc (BBIO) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.17. Which is the better fit depends on your goals.
| BBIO | VWO | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | — |
52-Week High | $90.17 | $61.24 |
52-Week Low | $44.81 | $49.54 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
VWO, the Vanguard FTSE Emerging Markets ETF, trades at $58.79, down 1.84% on the day amid a bearish technical signal. The fund's key financial ratios are not available in the data, but recent news highlights its low expense ratio of 0.06% and focus on emerging markets excluding South Korea, which has impacted performance relative to peers. Technical indicators show mixed signals with neutral oscillators and bearish moving averages.
The outlook for VWO is influenced by emerging market flows and geopolitical factors, with opportunities in diversification away from U.S. stocks but risks from China's economic drag and expense ratio comparisons with competitors like EEM. Investor sentiment is cautious due to regional tensions and allocation debates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
